Search

Your search keyword '"Rogerio Lilenbaum"' showing total 128 results

Search Constraints

Start Over You searched for: Author "Rogerio Lilenbaum" Remove constraint Author: "Rogerio Lilenbaum"
128 results on '"Rogerio Lilenbaum"'

Search Results

1. Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403

2. Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of

3. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase 2 trial

4. Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622)

5. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018

6. Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer

7. Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

8. Preparing for Value-Based Payment: A Stepwise Approach for Cancer Centers

9. Optimizing Treatment Risk and Benefit for Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Right Treatment for the Right Patient

10. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016

11. Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction

12. Time-to-Treatment-Failure and Related Outcomes among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711)

13. Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer

14. Role of Chemoradiotherapy in Elderly Patients With Limited-Stage Small-Cell Lung Cancer

15. The Treatment of Advanced Lung Cancer in the Elderly

16. The Spectrum of Neuroendocrine Tumors: Histologic Classification, Unique Features and Areas of Overlap

17. A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non–Small-Cell Lung Cancer: Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG)

18. Development of Imminent Mortality Predictor for Advanced Cancer (IMPAC), a Tool to Predict Short-Term Mortality in Hospitalized Patients With Advanced Cancer

19. Non–Small Cell Lung Cancer, Version 1.2015

20. ASCO's Community Research Forum: Addressing Challenges of Community-Based Research from the Grass Roots

21. Final Results of a Phase I Prospective Trial Evaluating the Combination of Stereotactic Body Radiation Therapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) or Melanoma

22. OA10.04 Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403

23. ASCO Research Community Forum: Impact on clinical research

24. Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study

25. Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non–Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2

26. Stereotactic Body Radiotherapy in Patients With Stage I Non–Small-Cell Lung Cancer Aged 75 Years and Older: Retrospective Results From a Multicenter Consortium

27. Assessing Clinical Trial-Associated Workload in Community-Based Research Programs Using the ASCO Clinical Trial Workload Assessment Tool

28. Combining EGF receptor inhibitors with chemotherapy or chemoradiotherapy in patients with non-small-cell lung cancer

29. Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

30. Simple interventions to decrease use of chemotherapy in patients at the end of life

31. Final results of a phase I prospective trial evaluating the combination of stereotactic body radiotherapy (SBRT) with concurrent pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC) or melanoma

32. Development of a dashboard for end-of-life care at an academic hospital

33. Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab

34. Differences in Clinical Trial Patient Attributes and Outcomes According to Enrollment Setting

35. Randomized Phase II Trial of Docetaxel Plus Cetuximab or Docetaxel Plus Bortezomib in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2: CALGB 30402

36. Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer

37. Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials

38. New Treatment Strategies in Patients with Advanced Non–Small-Cell Lung Cancer and Performance Status 2

40. New Horizons in Chemotherapy: Platforms for Combinations in First-Line Advanced Non-small Cell Lung Cancer

41. Summary Statement Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference Assessing Opportunities for Combination Therapy

42. Efficacy and Safety of Oxaliplatin and Gemcitabine with Bevacizumab in Advanced Non-small Cell Lung Cancer

43. Measuring Clinically Significant Chemotherapy-Related Toxicities Using Medicare Claims From Cancer and Leukemia Group B (CALGB) Trial Participants

44. Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2

45. Should Health-Related Quality of Life Be Measured in Cancer Symptom Management Clinical Trials? Lessons Learned Using the Functional Assessment of Cancer Therapy

46. Treatment of Non-small Cell Lung Cancer, Stage IV

47. A Randomized Phase II Trial of Two Schedules of Docetaxel in Elderly or Poor Performance Status Patients with Advanced Non-small Cell Lung Cancer

48. Expectations in the care of lung cancer

49. Non-Small Cell Lung Cancer, Version 6.2015

50. Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Catalog

Books, media, physical & digital resources